Hospital
Antelope Valley Health Care District
Antelope Valley Health Care District was paid $222.29M by Medicaid between Jan 2018 and Dec 2024, across 341 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoANTELOPE VALLEY HEALTH CARE DISTRICT
LANCASTER, CA 93534
LANCASTER, CA 93534
33aNPI1366419517assigned 03/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$222.29M
24GClaims2,405,107
24DCodes billed341
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#3 of 410
Median peer was paid$6.90M
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 361,218 | $27.18M | |
| 2019 | 373,336 | $36.83M | |
| 2020 | 313,911 | $31.28M | |
| 2021 | 294,099 | $31.02M | |
| 2022 | 353,125 | $35.96M | |
| 2023 | 380,305 | $33.92M | |
| 2024incomplete | 329,113 | $26.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 110,294 | 99,262 | $55.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 93,096 | 85,927 | $36.99M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 31,625 | 28,111 | $24.75M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 28,662 | 27,556 | $8.60M |
| 0450 | Emergency room services | 3.0% | 108,499 | 92,874 | $6.63M |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.4% | 111,297 | 99,095 | $5.24M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 37,618 | 33,484 | $3.90M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.7% | 59,993 | 52,786 | $3.69M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 12,655 | 12,296 | $2.90M |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.2% | 33,153 | 29,462 | $2.78M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 16,460 | 15,855 | $2.73M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 19,147 | 17,107 | $2.32M |
329 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 62,320 | $2.22M |
| 0270 | <1% | 31,288 | $2.22M | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 27,698 | $2.14M |
| 84484 | <1% | 36,220 | $1.88M | |
| 71045 | Radiologic examination, chest; single view | <1% | 40,883 | $1.86M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16,153 | $1.83M |
| Z7502 | <1% | 48,145 | $1.71M | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17,038 | $1.64M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 31,578 | $1.60M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 11,077 | $1.58M |
| G0378 | Hospital observation service, per hour | <1% | 3,304 | $1.53M |
| 81003 | <1% | 67,778 | $1.52M | |
| 81025 | <1% | 58,808 | $1.45M | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,602 | $1.43M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 7,437 | $1.37M |
| 0250 | <1% | 21,338 | $1.30M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,760 | $1.28M |
| 84702 | <1% | 8,398 | $1.27M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,028 | $1.25M |
| 99199 | Unlisted special service, procedure or report | <1% | 9,611 | $1.15M |
| 82948 | <1% | 31,514 | $1.10M | |
| 0762 | <1% | 5,262 | $1.07M | |
| 83690 | <1% | 42,550 | $1.00M | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 11,347 | $990K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,432 | $989K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,083 | $827K |
| 85027 | <1% | 92,522 | $800K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 7,884 | $735K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 8,437 | $718K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,933 | $704K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,699 | $699K |
| 80076 | <1% | 55,538 | $691K | |
| 81001 | <1% | 47,694 | $686K | |
| 59025 | Fetal non-stress test | <1% | 3,710 | $668K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 6,057 | $644K |
| J3490 | Unclassified drugs | <1% | 38,820 | $607K |
| 83880 | <1% | 14,733 | $604K | |
| 11043 | <1% | 1,402 | $530K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,810 | $481K |
| 87088 | <1% | 15,604 | $475K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 3,096 | $449K |
| 76830 | Ultrasound, transvaginal | <1% | 4,817 | $445K |
| 93971 | <1% | 4,102 | $438K | |
| 0682 | <1% | 152 | $437K | |
| 74022 | <1% | 4,351 | $429K | |
| 72100 | <1% | 4,782 | $424K | |
| 73562 | <1% | 4,485 | $415K | |
| 73030 | <1% | 4,810 | $415K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,773 | $400K |
| Z9725 | <1% | 8,817 | $379K | |
| 72040 | <1% | 3,856 | $360K | |
| 82962 | <1% | 10,286 | $326K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,229 | $311K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,540 | $302K |
| 73610 | <1% | 3,026 | $301K | |
| 73630 | <1% | 3,301 | $292K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,337 | $285K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,521 | $282K |
| 85018 | <1% | 9,214 | $270K | |
| 87430 | <1% | 3,107 | $265K | |
| Z7500 | <1% | 7,694 | $262K | |
| 73620 | <1% | 2,705 | $259K | |
| 84703 | <1% | 4,192 | $246K | |
| 0160 | <1% | 3,029 | $239K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,371 | $236K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 24,557 | $232K |
| 73130 | <1% | 2,462 | $228K | |
| 74018 | <1% | 2,923 | $221K | |
| 73120 | <1% | 2,009 | $203K | |
| 0272 | <1% | 2,555 | $202K | |
| 0360 | <1% | 1,273 | $199K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,033 | $196K |
| 93970 | <1% | 1,095 | $193K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 839 | $181K |
| 73502 | <1% | 2,555 | $179K | |
| 96376 | <1% | 5,447 | $177K | |
| 0637 | <1% | 44,538 | $177K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 5,362 | $174K |
| 73600 | <1% | 1,936 | $173K | |
| 73590 | <1% | 2,199 | $173K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,541 | $170K |
| 76770 | <1% | 1,833 | $168K | |
| 85730 | <1% | 22,686 | $156K | |
| 76870 | <1% | 1,341 | $152K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 25,902 | $147K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,534 | $146K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 30,569 | $146K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,237 | $144K |
| 73110 | <1% | 1,646 | $140K | |
| Z7610 | <1% | 15,918 | $139K | |
| 93308 | <1% | 830 | $139K | |
| 73090 | <1% | 1,988 | $138K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 956 | $138K |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 877 | $127K |
| 86901 | <1% | 14,455 | $122K | |
| 0370 | <1% | 1,324 | $121K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,191 | $121K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,953 | $119K |
| 70486 | <1% | 833 | $115K | |
| 85610 | <1% | 25,981 | $113K | |
| 87186 | <1% | 4,640 | $112K | |
| 36430 | <1% | 578 | $111K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,158 | $111K |
| Z1034 | <1% | 1,573 | $109K | |
| 90715 | <1% | 3,401 | $109K | |
| A9270 | Non-covered item or service | <1% | 41,276 | $109K |
| 83605 | <1% | 5,885 | $106K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,027 | $106K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,019 | $104K |
| 76857 | <1% | 1,428 | $101K | |
| 0710 | <1% | 1,701 | $97K | |
| 73100 | <1% | 1,231 | $96K | |
| 0301 | <1% | 2,858 | $95K | |
| 73080 | <1% | 1,138 | $93K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,671 | $88K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14,830 | $84K |
| 82731 | <1% | 519 | $83K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 632 | $82K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 540 | $82K |
| 87420 | <1% | 920 | $81K | |
| 86850 | <1% | 9,151 | $80K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,316 | $78K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 431 | $76K |
| 80320 | <1% | 4,956 | $75K | |
| 87077 | <1% | 2,987 | $70K | |
| 84112 | <1% | 1,256 | $70K | |
| 70496 | <1% | 432 | $69K | |
| 80329 | <1% | 3,483 | $69K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,976 | $66K |
| 73564 | <1% | 661 | $65K | |
| 73140 | <1% | 659 | $64K | |
| 72110 | <1% | 626 | $63K | |
| 99000 | <1% | 3,864 | $60K | |
| 85379 | <1% | 4,831 | $59K | |
| 80053 | Comprehensive metabolic panel | <1% | 5,187 | $59K |
| 74021 | <1% | 625 | $59K | |
| 0761 | <1% | 1,332 | $57K | |
| 71100 | <1% | 613 | $56K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,484 | $56K |
| 70498 | <1% | 401 | $55K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,567 | $51K |
| 87040 | <1% | 3,350 | $51K | |
| 12001 | <1% | 761 | $48K | |
| 99221 | <1% | 1,163 | $48K | |
| 82550 | <1% | 2,553 | $47K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 331 | $46K |
| 86900 | <1% | 9,026 | $45K | |
| 83735 | <1% | 4,556 | $43K | |
| 84550 | <1% | 1,807 | $40K | |
| 94760 | <1% | 2,462 | $39K | |
| 29125 | <1% | 1,454 | $38K | |
| 72050 | <1% | 370 | $38K | |
| 70360 | <1% | 429 | $37K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 225 | $36K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,499 | $34K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,570 | $34K |
| 51702 | <1% | 711 | $32K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 277 | $31K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 182 | $31K |
| 96379 | <1% | 2,866 | $31K | |
| 0271 | <1% | 1,192 | $30K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,086 | $28K |
| 87070 | <1% | 1,305 | $28K | |
| 72072 | <1% | 307 | $27K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,230 | $27K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,707 | $26K |
| 82010 | <1% | 2,224 | $25K | |
| 73060 | <1% | 376 | $25K | |
| 82150 | <1% | 2,431 | $25K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 86 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 577 | $23K |
| 12002 | <1% | 464 | $23K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 168 | $22K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 136 | $22K |
| 73070 | <1% | 431 | $21K | |
| 12011 | <1% | 265 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 531 | $19K |
| 99001 | <1% | 711 | $19K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,193 | $19K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 3,556 | $19K |
| 10060 | <1% | 568 | $19K | |
| 73552 | <1% | 255 | $19K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 7,199 | $19K |
| 85384 | <1% | 1,192 | $18K | |
| 86923 | <1% | 381 | $17K | |
| 87210 | <1% | 1,006 | $16K | |
| Z6500 | <1% | 82 | $16K | |
| 84481 | <1% | 1,051 | $16K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,434 | $15K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,547 | $15K |
| 82805 | <1% | 436 | $15K | |
| 29505 | <1% | 450 | $15K | |
| 84100 | <1% | 1,792 | $15K | |
| 82803 | <1% | 579 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,518 | $14K |
| 0300 | <1% | 1,738 | $14K | |
| 86920 | <1% | 135 | $14K | |
| 82140 | <1% | 857 | $13K | |
| 82248 | <1% | 722 | $13K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,725 | $13K |
| 99070 | <1% | 11,116 | $12K | |
| 70491 | <1% | 69 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 113 | $11K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,029 | $11K |
| 84439 | <1% | 1,571 | $11K | |
| 31720 | <1% | 118 | $11K | |
| 85362 | <1% | 1,084 | $11K | |
| 80055 | <1% | 227 | $11K | |
| 72131 | <1% | 90 | $11K | |
| 0259 | <1% | 5,334 | $11K | |
| 85652 | <1% | 2,969 | $11K | |
| Z1032 | <1% | 51 | $10K | |
| 84156 | <1% | 895 | $10K | |
| 86592 | <1% | 725 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 76 | $9K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,683 | $9K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,632 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,127 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 73 | $8K |
| 90714 | <1% | 443 | $8K | |
| 59425 | <1% | 68 | $8K | |
| 0324 | <1% | 922 | $7K | |
| 82570 | <1% | 1,033 | $7K | |
| 80061 | Lipid panel | <1% | 1,257 | $7K |
| 87205 | <1% | 698 | $7K | |
| 82247 | <1% | 831 | $6K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,596 | $5K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 346 | $5K |
| 99499 | <1% | 12 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,168 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,089 | $4K |
| 99072 | <1% | 4,962 | $4K | |
| 86141 | <1% | 137 | $4K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 15 | $4K |
| 86140 | <1% | 765 | $4K | |
| 76604 | <1% | 47 | $4K | |
| 74019 | <1% | 41 | $4K | |
| 87081 | <1% | 314 | $4K | |
| 29105 | <1% | 71 | $3K | |
| 76937 | <1% | 71 | $3K | |
| Z6400 | <1% | 268 | $3K | |
| 71020 | <1% | 118 | $3K | |
| 82728 | <1% | 193 | $3K | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 329 | $3K |
| 72070 | <1% | 39 | $3K | |
| 83615 | <1% | 196 | $3K | |
| 29130 | <1% | 89 | $3K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,942 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 285 | $2K |
| 51701 | <1% | 44 | $2K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 314 | $2K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 652 | $2K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 18 | $2K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 13 | $2K |
| 83550 | <1% | 181 | $2K | |
| 87340 | <1% | 167 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $2K |
| 88342 | <1% | 397 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 258 | $2K |
| A4649 | Surgical supply; miscellaneous | <1% | 99 | $1K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $1K |
| 96367 | <1% | 41 | $1K | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 62 | $1K |
| 71250 | <1% | 12 | $1K | |
| 82950 | <1% | 201 | $1K | |
| 88313 | <1% | 268 | $1K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 70 | $1K |
| Z6410 | <1% | 93 | $1K | |
| 99218 | <1% | 48 | $1K | |
| 85045 | <1% | 171 | $1K | |
| 29515 | <1% | 27 | $945.20 | |
| 96368 | <1% | 57 | $937.45 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 48 | $911.34 |
| 0306 | <1% | 849 | $908.52 | |
| 0636 | <1% | 540 | $871.06 | |
| 16020 | <1% | 13 | $847.42 | |
| Z7514 | <1% | 13 | $760.11 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 167 | $753.41 |
| 0320 | <1% | 68 | $697.11 | |
| 86703 | <1% | 37 | $611.80 | |
| 94762 | <1% | 19 | $558.04 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 146 | $537.31 |
| 84152 | <1% | 12 | $321.95 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 70 | $310.13 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 89 | $245.81 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 40 | $231.37 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 95 | $211.30 |
| 0460 | <1% | 90 | $210.00 | |
| 0258 | <1% | 712 | $208.20 | |
| 0760 | <1% | 504 | $171.75 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 24 | $170.78 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 36 | $167.83 |
| 49083 | <1% | 17 | $160.00 | |
| 84145 | <1% | 12 | $157.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 224 | $155.24 |
| 0305 | <1% | 1,467 | $149.66 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 49 | $143.00 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 18 | $111.98 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 162 | $102.68 |
| 88304 | <1% | 37 | $95.58 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 50 | $83.53 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $72.57 |
| 0730 | <1% | 325 | $70.56 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 14 | $66.73 |
| 0402 | <1% | 114 | $60.11 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 31 | $55.18 |
| 0302 | <1% | 1,132 | $26.99 | |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 18 | $25.20 |
| 0307 | <1% | 634 | $20.99 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 26 | $13.23 |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | <1% | 96 | $9.56 |
| 85014 | <1% | 18 | $3.75 | |
| 84153 | <1% | 12 | $1.61 | |
| 0255 | <1% | 52 | $1.54 | |
| 0206 | <1% | 454 | $0.55 | |
| 0121 | 0% | 18 | $0.00 | |
| 0309 | 0% | 93 | $0.00 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | 0% | 15 | $0.00 |
| 0122 | 0% | 203 | $0.00 | |
| 0470 | 0% | 51 | $0.00 | |
| 0424 | 0% | 14 | $0.00 | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 0% | 13 | $0.00 |
| 0771 | 0% | 241 | $0.00 | |
| 0721 | 0% | 57 | $0.00 | |
| 0171 | Inj, epinephrine (belcher) | 0% | 66 | $0.00 |
| 0352 | 0% | 109 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 12 | $0.00 |
| 0310 | 0% | 47 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHONG, KRISTINA (BOARD OF DIRECTORS- CHAIR)